Monitor stock price and equity levels closely over the next year, as any failure to maintain the $1.00 bid price or $2.5 million equity threshold will trigger an immediate delist risk without a second chance to cure. This creates elevated near-term execution risk despite current compliance.
Price Chart
Executive Summary
FibroBiologics announced it has regained compliance with all Nasdaq listing requirements, including the $1.00 bid price and $2.5 million stockholders' equity rules, resolving prior delisting concerns. However, the company remains under a one-year monitoring period for both criteria, with no cure period available if it falls out of compliance again.
Key Facts
- FibroBiologics has regained compliance with Nasdaq's $1.00 bid price and $2.5 million stockholders' equity listing requirements.
- The company is subject to a one-year monitoring period for both the bid price and equity rules, starting April 17, 2026, and March 9, 2026, respectively.
- If the company fails to maintain compliance during the monitoring periods, it will face an immediate delist determination without a cure period, though it may request a hearing.
Financial Impact
No direct financial impact, but avoids potential delisting and associated negative market reaction. Compliance removes immediate overhang on stock price.
Risk Factors
- Risk of delisting if bid price falls below $1.00 or stockholders' equity drops below $2.5 million at any point during the one-year monitoring period.
- Limited ability to raise capital or regain compliance if issues re-emerge, given no additional cure period will be granted.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-164018 |
| Document: fblg-ex99_1.htm | 0001193125-26-164018 |
| Document: 0001193125-26-164018-index-headers.html | 0001193125-26-164018 |
| Document: 0001193125-26-164018-index.html | 0001193125-26-164018 |
| Document: 0001193125-26-164018.txt | 0001193125-26-164018 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 8, 2026 17d ago | 8-K | $1.13 $0.9710 | ▲ +14.07% | ▲ +12.10% | $0.9221 (+18.40%) |
Sep 15, 2026 5w ago | 8-K | $1.44 $1.43 | ▼ −0.69% | ▼ −1.51% | $0.9221 (−35.97%) |
Aug 24, 2026 9w ago | 8-K | $1.35 $1.72 | ▲ +27.41% | ▲ +26.94% | $0.9221 (−31.70%) |
Jul 31, 2026 12w ago | Press Release | $0.7910 $0.9800 | ▲ +23.89% | ▲ +21.87% | $0.9221 (+16.57%) |
Jul 17, 2026 14w ago | EFFECT | $0.8349 $0.7355 | ▲ +11.91% | ▲ +11.22% | $0.9221 (−10.44%) |
Jul 9, 2026 15w ago | 8-K | $0.8610 $0.8398 | ▼ −2.46% | ▼ −2.33% | $0.9221 (+7.10%) |
Jun 29, 2026 16w ago | 8-K | $0.9477 $0.8687 | ▲ +8.34% | ▲ +8.94% | $0.9221 (+2.70%) |
May 11, 2026 24w ago | Press Release | $0.9900 $1.09 | ▲ +10.10% | ▲ +10.19% | $0.9221 (−6.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers